1. Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non–Small-cell Lung Cancer
   Florent Ginestet et al, 2018, Clinical Lung Cancer CrossRef
2. Comment on: “Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study)”
   Arnaud Uguen, 2017, Targeted Oncology CrossRef
3. Combining ALK Fluorescent In Situ Hybridization and Immunohistochemistry to Analyze Multiple Non–Small Cell Lung Carcinoma Samples per Patient Reveals Intermethod and Intersample-discrepant Results
   Laetitia Lambros et al, 2019, Applied Immunohistochemistry & Molecular Morphology CrossRef
4. Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens
   Lukas Bubendorf et al, 2017, European Respiratory Review CrossRef
5. Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice
   Paul Hofman, 2021, Cells CrossRef
6. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer
   Anne McLeer-Florin et al, 2018, Lung Cancer CrossRef
7. Benefit of crizotinib in a lung cancer patient with discordant ALK testing results
   Steven Grocholski et al, 2018, Cancer Treatment and Research Communications CrossRef
8. Asbestos-related lung cancers are rarely associated with ALK, ROS1 and RET rearrangements
   Marie Uguen et al, 2018, European Respiratory Journal CrossRef
9. Random Colocalization and Split of ALK Break Apart Probe Signals: Potential Concerns in the Real‐Life Diagnosis of Non‐Small‐Cell Lung Cancer
   Arnaud Uguen, 2018, Cytometry Part A CrossRef